Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)

There is no proven preventative therapy or vaccine against COVID-19. Theinfection has spread rapidly and there has already been a substantial adverse impact on the global economy. Healthcare workers have been affected disproportionately in the continuing pandemic. Significant infection rates in this...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Schilling, WHK, Callery, JJ, Taylor, W, Mukaka, M, Ekkapongpisit, M, Watson, JA, Chandna, A, Panapipat, S, Tubprasert, J, Yuentrakul, P, Waithira, N, Cope, T, Dhorda, M, Cruz, C, von Seidlein, L, Milton, J, LLewelyn, M, Adler, A, Chotivanich, K, Cheah, PY, Ashley, EA, Mayxay, M, Dondorp, AM, Phumratanaprapin, W, Day, NPJ, White, N
Natura:	Journal article
Lingua:	English
Pubblicazione:	F1000 Research Ltd 2020

Documenti analoghi

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
di: Schilling, WHK, et al.
Pubblicazione: (2024)

Chloroquine, hydroxychloroquine and COVID-19
di: Erickson, T. B., et al.
Pubblicazione: (2020)

COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
di: White, NJ, et al.
Pubblicazione: (2020)

Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine
di: Lotery, A, et al.
Pubblicazione: (2018)

Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine
di: Yusuf, IH, et al.
Pubblicazione: (2018)

Chloroquine and Hydroxychloroquine: Potentially Inappropriate Medications for Older Adults?
di: Milton Gorzoni
Pubblicazione: (2024-10-01)

Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine
di: Seidu A. Richard, et al.
Pubblicazione: (2020-01-01)

Retinal Toxicity and the Use of Hydroxychloroquine and Chloroquine in the Current Management of COVID-19
di: Romulo N. Aguilar, MD, PhD, et al.
Pubblicazione: (2020-06-01)

Early detection of the retinal bioelectrical dysfunction in patients treated by chloroquine/hydroxychloroquine
di: Wojciech Lubiński, et al.
Pubblicazione: (2024-12-01)

Measuring the energy for the molecular graphs of antiviral agents: Hydroxychloroquine, Chloroquine and Remdesivir
di: Muhammad Haroon Aftab, et al.
Pubblicazione: (2024-01-01)

Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy
di: Chandler, L, et al.
Pubblicazione: (2020)

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
di: Gbinigie, O, et al.
Pubblicazione: (2020)

Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine
di: Whittaker, DG, et al.
Pubblicazione: (2021)

Hydroxychloroquine and Chloroquine Toxicity as Reported by Medical Toxicologists to the Toxicology Investigators Consortium (ToxIC) Registry
di: Griswold, Matthew K., et al.
Pubblicazione: (2022)

Hydroxychloroquine and Chloroquine Toxicity as Reported by Medical Toxicologists to the Toxicology Investigators Consortium (ToxIC) Registry
di: Griswold, Matthew K., et al.
Pubblicazione: (2022)

Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine
di: Latarissa IR, et al.
Pubblicazione: (2025-01-01)

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
di: Cathrine Axfors, et al.
Pubblicazione: (2021-04-01)

Joint recommendations for retinal screening in long‐term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018
di: Yusuf, IH, et al.
Pubblicazione: (2018)

The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary
di: Yusuf, IH, et al.
Pubblicazione: (2018)

Artificial intelligence for detection of retinal toxicity in chloroquine and hydroxychloroquine therapy using multifocal electroretinogram waveforms
di: Mikhail Kulyabin, et al.
Pubblicazione: (2024-10-01)

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
di: Axfors, C, et al.
Pubblicazione: (2021)

Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
di: Cathrine Axfors, et al.
Pubblicazione: (2024-02-01)

The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary
di: Yusuf, IH, et al.
Pubblicazione: (2021)

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
di: Luvira, V, et al.
Pubblicazione: (2024)

The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
di: Schilling, WHK, et al.
Pubblicazione: (2021)

Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials
di: Nathália Mariana Santos Sansone, et al.
Pubblicazione: (2024-09-01)

Chloroquine sulphate and chloroquine phosphate (chloroquine diphosphate)
di: 982 SIRIM

Effect of antiretroviral therapy on plasma concentrations of chloroquine and desethyl-chloroquine
di: Ippolito, M, et al.
Pubblicazione: (2018)

Pharmacometrics of high dose ivermectin in early COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
di: Schilling, WHK, et al.
Pubblicazione: (2023)

Drug Interactions and Side Effects of Co-Administration of Chloroquine/Hydroxychloroquine and Azithromycin: on the Issue of Rational Pharmacotherapy of Patients with COVID-19 with Antimalarial Drugs
di: O. V. Gaisenok
Pubblicazione: (2020-07-01)

Drug–Drug Interactions of Hydroxychloroquine and Chloroquine in Older Patients with COVID-19 during the First Pandemic Waves: The GeroCovid Observational Study
di: Caterina Trevisan, et al.
Pubblicazione: (2024-05-01)

Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan
di: Wangchuk, S, et al.
Pubblicazione: (2016)

Hydroxychloroquine retinopathy: an emerging problem.
di: Latasiewicz, M, et al.
Pubblicazione: (2017)

The treatment of chloroquine-resistant malaria.
di: van Vugt, M, et al.
Pubblicazione: (1999)

Hydroxychloroquine retinopathy.
di: Yusuf, I, et al.
Pubblicazione: (2017)

Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels.
di: Baird, J, et al.
Pubblicazione: (1997)

Failure of chloroquine-erythromycin and chloroquine-tetracycline combinations in treatment of chloroquine-resistant falciparum malaria in eastern Thailand.
di: Phillips, R, et al.
Pubblicazione: (1984)

High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS
di: Kaewkhao, K, et al.
Pubblicazione: (2019)

Comparison of the umulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria
di: Chu, C, et al.
Pubblicazione: (2018)

Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in plasmodium vivax malaria
di: Chu, C, et al.
Pubblicazione: (2018)